| INTRODUC TI ON
Lipoprotein lipase (LPL), a member of the serine esterase family, was discovered in 1943 and is mainly produced and secreted by myocardial, skeletal muscle, and adipose tissue. 1 After synthesis, it is secreted and transported to the luminal surfaces of vascular endothelial cells and embedded in the inner walls of vessels by ion reaction with heparan sulfate proteoglycan or glycosylphosphatidylinositol. 2 The main physiological function of LPL in humans is to hydrolyze chitos an particles in plasma and triglycerides in very low-density lipoproteins, resulting in free fatty acids entering the myocardium and skeletal muscle to undergo oxygenolysis, release energy, or re-synthesize triglycerides stored in adipose tissue. 3 LPL is a rate-limiting enzyme in triglyceride degradation, which plays important roles in lipid metabolism, insulin resistance, and adipocyte differentiation. 1 The human LPL gene is located on chromosome 8 short arm 8p22
and comprises ten exons and nine introns, including 30 kp bases,
Background:
Severe hypertriglyceridemia usually results from a combination of genetic and environmental factors and is most often attributable to mutations in the lipoprotein lipase (LPL) gene.
Objectives:
The aim of this study was to identify rare mutations in the LPL gene causing severe hypertriglyceridemia.
Methods:
A Chinese infant who presented classical features of severe hypertriglyceridemia recruited for DNA sequencing of the LPL gene. The pathogenicity grade of the variants was defined based on the prediction of pathogenicity using in silico prediction tools. Review some studies to understand the molecular mechanisms underlying the severe hypertriglyceridemia.
Results: We identified a rare mutation in the LPL gene causing severe hypertriglyceridemia: a nucleotide substitution (c.836T>G) resulting in a leucine to arginine substitution at position 279 of the protein (p.Leu279Arg).The pathogenicity of the variant was predicted by in silico analysis using PolyPhen2 and SIFT prediction programs, which indicated that mutation p.Leu279Arg is probably harmful. We have also reviewed published studies concerning the molecular mechanisms underlying severe hypertriglyceridemia. A missense mutation in the 6 exon of the LPL gene is reportedly associated with LPL deficiency.
Conclusions:
We have here identified a rare pathogenic mutation in the LPL gene in a Chinese infant with severe hypertriglyceridemia.
K E Y W O R D S
heterozygous, Hypertriglyceridemia, LPL gene, missense that encode a 475 amino acid lipoprotein. 4, 5 In this article, we report a case of heterozygous LPL mutation in an infant with severe hypertriglyceridemia and convulsions. The child's parents gave informed consent for the tests on the proband and family members, which were approved by the Ethics Committee of our institution.
| MATERIAL S AND ME THODS

| Subjects
| DNA isolation and sequencing
With informed consent, 2-mL blood samples were extracted from the proband and his family members and ethylenediaminetetraacetic acid added. A Qiagen FlexiGene DNA Kit (Qiagen, Hilden, Germany) was used to extract genomic DNA from these samples according to the manufacturer's instructions.
All LPL exons and their flanking intronic regions were amplified by a primer set design based on the sequence of the LPL gene (NC_000008.11) in GenBank. The primers were diluted, after which ABI PCR amplification was performed according to primer conditions. The PCR products were electrophoresed by 1% agarose gel electrophoresis to identify, purify, and recover the products, which were then sequenced. The sequencing products were run on a Genetic Analyzer 3730 (Applied Biosystems).
| Plasma lipid analysis
A morning fasting blood sample was taken, and serum concentrations of TC (cholesterol oxidase method), TG (glycerol phosphate oxidase method), HDL-C (phosphotungstic acid-magnesium precipitation method), LDL-C (polyethylene sulfuric acid precipitation method), and apoA I, apoB, and Lp (a) (immunoturbidimetry method)
were measured using a 7600 Automatic Biochemical Analyzer (Hitachi High-Technologies, Tokyo, Japan).
| Bioinformatic analysis
The conserved amino acid sequences of LPL were partially analyzed by multiple sequence alignment. The pathogenicity of the variants was predicted using in silico prediction tools, namely PolyPhen2
(http://genetics.bwh.harvard.edu/pph2/index.shtml) and SIFT (http://sift.jcvi.org).
| RE SULT
| Clinical data analysis
As shown in Table 1 , the lipid profiles of the proband and his family were compared. Triglycerides were very high and high-density lipoprotein was low in the proband and his sister showed moderate hypertriglyceridemia, whereas his parents had normal lipid profiles ( Figure 1 ). When he first diagnosed chylomicronemia, the doctor suggested weaning. The TG concentration after weaning was 22.07 mmol/L. The proband's parents were of Zhuang ethnicity from Nanning, Guangxi Zhuang Autonomous Region in China, and denied both in-law marriage and any relevant family history. 
| Analysis of mutations in the LPL
| Bioinformatic analysis
Partial amino acid sequences of LPL in 11 species were obtained and found to have highly conserved p.L279 leucine sequences ( Figure 3 ).
In silico analysis using PolyPhen2 and SIFT prediction programs indicated that mutation p.Leu279Arg is probably harmful.
| D ISCUSS I ON
Familial lipoprotein lipase deficiency is rare and caused by mutations in the LPL gene that have an autosomal-recessive pattern of inheritance. 9 In this study, we report a Chinese infant with hypertriglyceridemia and convulsions who we found to have a heterozygous missense mutation in the LPL gene. Unfortunately, the severity of the hypertriglyceridemia-associated phenotype was not reported. The patient we here describe has a heterozygous nonsense mutation (c.836T>G-p.Leu279Arg) of LPL that is associated with a severe hypertriglyceridemia phenotype. In silico PolyPhen2 and SIFT prediction programs have indicated that mutation p.Leu279Arg is probably harmful. In conclusion, we here identified a rare missense mutation of In LPL deficiency; has no effect on the specific activity of the enzyme; has a mild effect on the secretion of the mutant enzyme; the total LPL mass is reduced compared to that of the wild-type construct 
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